However, on the basis of previously reported relapse trials, our cohort appears to be a comparable collective in terms of risk factors (eg, number of relapses, time to relapse, and MYCN amplification status).2,3,13 The results of trials evaluating the role of combinational treatment of anti-GD2 antibodies with chemotherapy in rHR-NB have recently reported comparable ORRs.3,4 These approaches avoid potential side effects of HSCT, especially GvHD, whereas in our approach, donor-derived effector cells in combination with antibody treatment could provide a stronger, longer-lasting tumor control. This evidence concerns the gene MYCN and neuroblastoma.